肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect and safety of Feitai Capsules combined with Western antituberculosis drug in the treatment of preliminary smear-positive pulmonary tuberculosis.Methods From January 2016 to December 2018, 150 patients with newly diagnosed smear-positive pulmonary tuberculosis who were treated in the Yingtan People′s Hospital (Railway Branch) were selected as the research subjects.The patients were randomly divided into the control group (n=75) and study group (n=75) using computer-generated random number.In the control group, 2HRZE/4HR regimen was used, while in the study group, Feitai Capsules on the basis of the control group were added.The clinical efficacy of the two groups was compared.The sputum negative conversion rate of the two groups was compared.The lung lesion absorption, cavity closure and clinical symptom improvement were compared between the two groups.The total incidence of adverse reactions was compared between the two groups.Results The total effective rate in the study group was higher than that in the control group, and the difference was statistically significant (P＜0.05).The sputum negative conversion rate in the study group was higher than that in the control group at the end of 2, 5, and 6 months treatment,the differences were statistically significant(P＜0.05).After treatment,the lung lesion absorption rate,cavity closure rate, and clinical symptom improvement rate in the study group were higher than those in the control group, and the differences were statistically significant (P＜0.05).The lesion absorption time, cavity closure time and clinical symptom improvement time of patients in the study group were all shorter than those in the control group, with statistically significant differences (P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Feitai Capsules combined with Western antituberculosis drug for the treatment of smear-positive pulmonary tuberculosis are effective and safe.Feitai Capsules can be used as an adjuvant treatment for preliminary smear-positive tuberculosis.

Key words： Feitai Capsules Tuberculosis Sputum negative conversion rate Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Xian-hui
	YI Shu-lin

Cite this article:

WU Xian-hui,YI Shu-lin. Clinical effect of Feitai Capsules combined with Western antituberculosis drug in the treatment of preliminary smear-positive pulmonary tuberculosis[J]. 中国当代医药, 2020, 27(13): 137-140.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I13/137

[1]	Kuo HC，Chen SC，Lin HK，et al.Concomitant pediatric abdominal and pulmonary tuberculosis[J].Pediatr Neonatol，2019，60（6）：695-696.
[2]	Li T，Cheng Q，Li C，et al.Evidence for heterogeneity in China′s progress against pulmonary tuberculosis：uneven reductions in a major center of ongoing transmission，2005-2017[J].BMC Infect Dis，2019，19（1）：615.
[3]	Wu DC，Averbukh LD，Wu GY.Diagnostic and therapeutic strategies for peritoneal tuberculosis：a review[J].J Clin Transl Hepatol，2019，7（2）：140-148.
[4]	Teo AKJ，Singh SR，Prem K，et al.Delayed diagnosis and treatment of pulmonary tuberculosis in high-burden countries：a systematic review protocol[J].BMJ Open，2019，9（7）：e029807.
[5]	Kumar NP，Moideen K，Banurekha VV，et al.Plasma proinflammatory cytokines are markers of disease sever ity and bacterial burden in pulmonary tuberculosis[J].Open Forum Infect Dis，2019，6（7）：257.
[6]	中华人民共和国卫生部疾病控制局，中华人民共和国卫生部医政司，中国疾病预防控制中心.中国结核病防治规划实施工作指南（2008年）[M].北京：中国协和医科大学出版社，2008：89.
[7]	符宗望.手术联合抗结核药物与单纯抗结核药物治疗在空洞型肺结核中的效果比较[D].南宁：广西医科大学，2019.
[8]	中华医学会结核病学分会.肺结核诊断和治疗指南[J].中华结核和呼吸杂志，2001，20（2）：70-74.
[9]	Saktiawati AMI，Putera DD，Setyawan A，et al.Diagnosis of tuberculosis through breath test：A systematic review[J].E Bio Med，2019，46：202-214.
[10]	Wang B，Li M，Ma H，et al.Computed tomography-based predictive nomogram for differentiating primary progressive pulmonary tuberculosis from community-acquired pneumonia in children[J].BMC Med Imaging，2019，19（1）：63.
[11]	Alelign A，Petros B，Ameni G.Smear positive tuberculosis and genetic diversity of M.tuberculosis isolates in individuals visiting health facilities in South Gondar Zone，Northwest Ethiopia[J].PLoS One，2019，14（8）：e0216437.
[12]	Kaba O，Kara M，Odacilar CA，et al.Evaluation of cases of pediatric extrapulmonary tuberculosis：a single center experience[J].Turk Pediatri Ars，2019，54（2）：86-92.
[13]	王姬，郑雁，冯马龙.肺泰胶囊联合抗结核治疗方案治疗复治肺结核的临床观察[J].中国中西医结合杂志，2017，37（10）：1196-1200.
[14]	赵晓虎.肺泰胶囊联合常规西药治疗耐药性肺结核49 例[J].中国药业，2014，23（24）：122-124.
[15]	李孝东，周宏宇，李志伟，等.肺结核短程化疗加服肺泰胶囊疗效观察[J].临床肺科杂志，2012，17（11）：2040-2041.